ArticleJournal of pharmaceutical policy and practice2026
An analysis of the registration of essential medicines in Namibia: a proxy measure of the availability of essential medicines.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many African countries, including Namibia, face challenges with the availability of essential medicines, impacting health outcomes. This study aimed to evaluate the availability of essential medicines in Namibia by examining the registration of medicines on the Namibia Essential Medicines List (NEMList) as a proxy. Methods: An in-depth analysis of the registration of essential medicines was carried out by comparing medicines in the NEMList against registered medicines on the Namibian Human Medicines Register as of February 2024. Microsoft Excel was used to capture details about the generic names of medicines, strengths, and dosage forms in which the medicines were available. A sub-analysis of antibiotics, which classified them using the Access, Watch and Reserve (AWaRe) classification, was also conducted. Results: A high proportion of essential medicines listed in the NEMList, 80.2% (386/481) are registered in the country. However, essential medicines only accounted for 23.7% (1,288/5,444) of all medicines on the Namibian Human Medicines Register. Among the essential medicines registered in Namibia, only 45.5% (176/386) had at least three registered products. Of the 55 antibiotics on the NEMList, 94.5% (52/55) had registered products, with 96.2% (25/26), 92.0% (23/25) and 100% (4/4) of Access, Watch and Reserve group antibiotics having registered products, respectively. Despite the high proportions of registered essential antibiotics, only 65.4% of Access group antibiotics, 68.0% of Watch group antibiotics and 25.0% of Reserve antibiotics had at least three registered products. Conclusion: Registration of essential medicines is crucial to ensure access and availability. Further studies are needed to understand the bottlenecks encountered by the Namibia Medicines Regulatory Council (NMRC) in registering essential medicines. Concerted programmes and policies to strengthen regional harmonisation of medicines registration should be developed, and essential medicines should be prioritised.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.